Sosero YL, Ferwerda B, Tocino MTP, Belloso DR, Gomez-Garre P, Faouzi J, Pavelka L, Marques TM, Gomes CPC, Kolodkin A, May P, Milanowski LM, Wszolek ZK, Uitti RJ, Heutink P, van Hilten J, Simon DK, Eberly S, Fernandez IA, Krohn L, Yu E, Freeman K, Rudakou U, Ruskey JA, Asayesh F, Menendez M, Pastor P, Ross O, Kruger R, Corvol JC, Koks S, Mir P, de Bie RMA, Iwaki H and Gan-Or Z. Dopamine pathway and Parkinson’s risk variants are associated with levodopa-induced dyskinesia. Movement Disorders. 2024. Preprint, PubMed
Month: October 2024
Genotype-Phenotype correlations in PRKN-associated Parkinson’s disease.
Menon PJ, Sambin S, Criniere-Boizet B, Courtin T, Tesson C, Casse F, Ferrien M, Mariani LL, Carvalho S, Lejeune FX, Rebbah S, Martet G, Houot M, Lanore A, Mangone G, Roze E, Vidailhet M, Aasly J, Gan-Or Z, Yu E, Dauvilliers Y, Zimprich A, Tomantschger V, Pirker W, Álvarez I, Pastor P, Di Fonzo A, Bhatia KP, Magrinelli F, Houlden H, Real R, Quattrone A, Limousin P, Korlipara P, Foltynie T, Grosset D, Williams N, Narendra D, Lin HP, Jovanovic C, Svetel M, Lynch T, Gallagher A, Vandenberghe W, Gasser T, Brockmann K, Morris HR, Borsche M, Klein C, Corti O, Brice A, Lesage S and Corvol JC. Genotype-Phenotype correlations in PRKN-associated Parkinson’s disease. npj Parkinson’s Disease. 2024. Preprint, PubMed
Genome-wide association study of REM sleep behavior disorder in Parkinson’s disease.
Sosero YL, Heilbron K, Fontanillas P, Norcliffe-Kaufmann L, Yu E, Rudakou U, Ruskey JA, Freeman K, Asayesh F, Brolin K, Swanberg M, Morris HR, Wu L, Real R, Pihlstrøm L, Tan M, Gasser T, Brockmann K, Liu H, Hu MTM, Grosset DG, Lewis SJG, Kwok JB, Pastor P, Alvarez I, Skorvanek M, Lackova A, Ostrozovicova M, Rizig M, 23andMe Research Team, The International Parkinson’s Disease Genomics Consortium, Krohn L and Gan-Or Z. Genome-wide association study of REM sleep behavior disorder in Parkinson’s disease. Under review. 2024. Preprint, PubMed
Genome-wide association study stratified by MAPT haplotypes identifies potential novel loci in Parkinson’s disease
Senkevich K, Bandres-Ciga S, Cisterna-García A, Yu E, Bustos BI, Krohn L, Lubbe SJ, Botía JA, the International Parkinson’s Disease Genomics Consortium (IPDGC) and Gan-Or Z. Genome-wide association study stratified by MAPT haplotypes identifies potential novel loci in Parkinson’s disease. Under review. Preprint, PubMed
APOE – e4 is not associated with pure-tone hearing thresholds, visual acuity or cognition, cross-sectionally or over 3 years of follow up in the Canadian Longitudinal Study on Aging.
Mick P, Kabir R, Karunatilake M, Kathleen Pichora-Fuller M, Young TL, Sosero Y, Gan-Or Z, Wittich W, Phillips NA. APOE – e4 is not associated with pure-tone hearing thresholds, visual acuity or cognition, cross-sectionally or over 3 years of follow up in the Canadian Longitudinal Study on Aging. Neurobiology of Aging. 2024. Preprint, PubMed
Autosomal dominant Parkinson’s disease caused by SNCA p.E46K mutation in a family with Russian ancestry.
Senkevich K, Miliukhina I, Zhuravlev A, Shumilova M, Beletskaia M, Skvortsova T, Yu E, Ahmad J, Asayesh F, Gan-Or Z, Emelyanov A and Pchelina S. Autosomal dominant Parkinson’s disease caused by SNCA p.E46K mutation in a family with Russian ancestry. Movement Disorders. 2024. PubMed
Lessons and future directions for GBA1 targeting therapies.
Gan-Or Z. Lessons and future directions for GBA1 targeting therapies. Lancet Neurology. 2023. PubMed
Machine learning nominates the inositol pathway and novel genes in Parkinson’s disease.
Epigenetic clock acceleration is linked to earlier onset and phenoconversion age in REM sleep behavior disorder.
MerTK is a mediator of alpha-synuclein fibril uptake by human microglia
Dorion MF, Yaqubi M, Senkevich K, Kieran NW, MacDonald A, Chen CXQ, Luo W, Wallis A, Shlaifer I, Hall JA, Dudley RWR, Glass IA; Birth Defects Research Laboratory; Stratton JA, Fon EA, Bartels T, Antel JP, Gan-Or Z, Durcan TM, Healy LM. MerTK is a mediator of alpha-synuclein fibril uptake by human microglia. Brain. 2024. Preprint, PubMed